All In Biotech

Drug Trial Radar · NCT02630706

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy (VERTIS-ASIA)

Last checked: Nov 20, 2026Latest source record: Dec 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 506 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

506

Actual

Start

Dec 16, 2015

Primary completion

Dec 27, 2017

Study completion Dec 27, 2017

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Dec 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the efficacy and safety of the addition of ertugliflozin to metformin monotherapy in Asian participants with Type 2 diabetes mellitis (T2DM) who have inadequate glycemic control on metformin monotherapy. The primary hypothesis is that the mean reduction from baseline in HbA1C for 15 mg and 5 mg ertugliflozin (tested sequentially) is greater than for placebo.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Ertugliflozin 5 mgDrug

    Ertugliflozin 5 mg oral tablet taken once daily

  • Ertugliflozin 15 mgDrug

    Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily

  • Placebo matching ertugliflozinDrug

    Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily

  • MetforminDrug

    Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

  • GlimepirideDrug

    Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)Time frame: Baseline and Week 26
  2. Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)Time frame: Baseline and Week 26
  3. Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)Time frame: Up to 28 weeks
  4. Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)Time frame: Up to 28 weeks
  5. Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)Time frame: Up to 26 weeks
  6. Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)Time frame: Up to 26 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.